Human Genome Editing and Sickle Cell Disease in Canada: Urgent and Unresolved Ethical Considerations

Authors

  • Maria Klimenko Centre for Health Care Ethics & Department of Health Sciences, Lakehead University, Thunder Bay, Ontario, Canada
  • Ryan Tonkens Centre for Health Care Ethics, Lakehead University; NOSM University, Thunder Bay, Ontario, Canada https://orcid.org/0009-0006-5007-1159

DOI:

https://doi.org/10.7202/1117873ar

Keywords:

Casgevy, equity, inclusion, ethics, human genome editing, justice, public engagement, sickle cell disease

Language(s):

English

Abstract

Some countries are already approving therapeutic applications of human genome editing. For example, recently the United Kingdom and USA have approved Casgevy as part of a treatment protocol for sickle cell disease. Should Canada follow this lead? Here we discuss the most important, yet unresolved, ethical issues in a Canadian context, and argue that much more public engagement and deliberation is needed.

Downloads

Published

2025-04-28

How to Cite

[1]
Klimenko M, Tonkens R. Human Genome Editing and Sickle Cell Disease in Canada: Urgent and Unresolved Ethical Considerations. Can. J. Bioeth 2025;8:120-4. https://doi.org/10.7202/1117873ar.

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.